StocksFundsScreenerSectorsWatchlists
HOLX

HOLX - Hologic Inc Stock Price, Fair Value and News

77.56USD+0.23 (+0.30%)Market Closed

Market Summary

HOLX
USD77.56+0.23
Market Closed
0.30%

HOLX Alerts

  • 3 major insider sales recently.

HOLX Stock Price

View Fullscreen

HOLX RSI Chart

HOLX Valuation

Market Cap

18.2B

Price/Earnings (Trailing)

35.34

Price/Sales (Trailing)

4.59

EV/EBITDA

22.54

Price/Free Cashflow

19.66

HOLX Price/Sales (Trailing)

HOLX Profitability

EBT Margin

15.83%

Return on Equity

11.07%

Return on Assets

6.08%

Free Cashflow Yield

5.09%

HOLX Fundamentals

HOLX Revenue

Revenue (TTM)

4.0B

Rev. Growth (Yr)

-5.69%

Rev. Growth (Qtr)

7.17%

HOLX Earnings

Earnings (TTM)

515.1M

Earnings Growth (Yr)

31.54%

Earnings Growth (Qtr)

172.08%

Breaking Down HOLX Revenue

Last 7 days

0.2%

Last 30 days

2.2%

Last 90 days

6.4%

Trailing 12 Months

-7.8%

How does HOLX drawdown profile look like?

HOLX Financial Health

Current Ratio

3.89

Debt/Equity

0.54

Debt/Cashflow

0.4

HOLX Investor Care

Buy Backs (1Y)

4.80%

Diluted EPS (TTM)

2.11

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20234.1B4.0B4.0B4.0B
20225.4B5.2B4.9B4.5B
20215.3B5.7B5.6B5.5B
20203.3B3.3B3.8B4.5B
20193.3B3.3B3.4B3.4B
20182.1B2.8B3.2B3.3B
20172.9B2.3B2.0B2.1B
20162.8B2.8B2.8B0
20152.6B2.7B2.7B2.7B
20142.5B2.5B2.5B2.6B
20132.3B2.5B2.5B2.5B
20121.9B1.9B2.0B2.2B
20111.1B1.5B1.8B1.8B
20101.4B1.1B819.1M839.2M
20091.7B1.6B1.6B1.6B
200801.2B1.7B1.7B
200700738.4M0

Tracking the Latest Insider Buys and Sells of Hologic Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 14, 2024
garrett scott t
acquired
508,471
30.927
16,441
-
Mar 14, 2024
garrett scott t
sold
-1,241,300
75.5
-16,441
-
Mar 08, 2024
crawford sally
acquired
241,703
26.74
9,039
-
Mar 08, 2024
crawford sally
sold
-690,607
76.403
-9,039
-
Mar 08, 2024
dockendorff charles j
sold
-111,648
76.21
-1,465
-
Mar 07, 2024
stewart stacey d.
acquired
-
-
1,572
-
Mar 07, 2024
wendell amy mcbride
acquired
-
-
1,572
-
Mar 07, 2024
garrett scott t
acquired
-
-
1,572
-
Mar 07, 2024
crawford sally
acquired
-
-
1,572
-
Mar 07, 2024
hantson ludwig
acquired
-
-
1,572
-

1–10 of 50

Which funds bought or sold HOLX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Apr 12, 2024
AdvisorNet Financial, Inc
reduced
-26.03
-1,006
4,210
-%
Apr 12, 2024
HARBOR INVESTMENT ADVISORY, LLC
added
10.5
2,939
17,229
-%
Apr 12, 2024
Ausdal Financial Partners, Inc.
reduced
-6.37
9,411
444,684
0.05%
Apr 12, 2024
DNB Asset Management AS
reduced
-2.03
846,447
13,113,300
0.07%
Apr 12, 2024
WASHINGTON CAPITAL MANAGEMENT, INC
new
-
618,223
618,223
0.50%
Apr 12, 2024
Financial Synergies Wealth Advisors, Inc.
unchanged
-
9.00
234
-%
Apr 12, 2024
ARMSTRONG ADVISORY GROUP, INC
unchanged
-
-
10,718
-%
Apr 12, 2024
Dynamic Advisor Solutions LLC
added
0.15
87,553
1,332,880
0.04%
Apr 12, 2024
Trinity Street Asset Management LLP
added
2.02
2,064,190
20,307,900
1.62%
Apr 12, 2024
Allen Mooney & Barnes Investment Advisors LLC
reduced
-0.62
74,993
990,839
0.19%

1–10 of 49

Are Funds Buying or Selling HOLX?

Are funds buying HOLX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own HOLX
No. of Funds

Unveiling Hologic Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
t. rowe price investment management, inc.
9.2%
22,071,713
SC 13G
Feb 13, 2024
vanguard group inc
11.53%
27,678,976
SC 13G/A
Jan 08, 2024
blackrock inc.
10.1%
24,263,694
SC 13G/A
Feb 14, 2023
t. rowe price investment management, inc.
9.5%
23,376,904
SC 13G
Feb 09, 2023
vanguard group inc
11.60%
28,519,496
SC 13G/A
Jan 24, 2023
blackrock inc.
9.6%
23,478,641
SC 13G/A
Feb 14, 2022
price t rowe associates inc /md/
16.4%
41,296,661
SC 13G/A
Feb 10, 2022
vanguard group inc
10.94%
27,500,693
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G/A
Feb 01, 2022
blackrock inc.
8.7%
21,888,278
SC 13G/A

Recent SEC filings of Hologic Inc

View All Filings
Date Filed Form Type Document
Mar 15, 2024
4
Insider Trading
Mar 14, 2024
144
Notice of Insider Sale Intent
Mar 12, 2024
8-K
Current Report
Mar 11, 2024
4
Insider Trading
Mar 11, 2024
4
Insider Trading
Mar 11, 2024
4
Insider Trading
Mar 11, 2024
4
Insider Trading
Mar 11, 2024
4
Insider Trading
Mar 11, 2024
4
Insider Trading
Mar 11, 2024
4
Insider Trading

Peers (Alternatives to Hologic Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
188.9B
40.1B
-5.73% 4.72%
33.01
4.71
-8.12% -17.45%
67.8B
19.5B
-0.88% -8.17%
53.97
3.48
4.02% -22.04%
22.9B
3.9B
-3.10% -11.00%
51.41
5.92
3.42% 23.09%
20.3B
14.8B
-3.77% -6.99%
7.66
1.37
2.12% 209.17%
MID-CAP
9.1B
3.5B
-1.99% 15.94%
32.07
2.62
4.97% 18.89%
9.1B
12.3B
-5.16% -14.19%
21.85
0.74
-2.44% -22.68%
8.8B
2.7B
-9.88% -37.29%
-13.77
3.29
-4.68% 82.43%
6.4B
4.0B
-5.94% -24.93%
-47.62
1.62
1.10% 85.84%
3.4B
366.4M
-0.71% 17.46%
-565.84
9.37
33.86% 89.83%
2.3B
6.6B
-6.94% -4.63%
11.73
0.35
2.78% -0.87%
SMALL-CAP
1.3B
3.2B
-3.79% -17.24%
-1.94
0.41
7.73% -1066.14%
376.4M
166.7M
-0.35% -8.55%
-4.55
2.26
6.67% -456.34%
253.5M
324.0M
17.88% -30.36%
-1.32
0.78
-3.19% -337.41%
47.8M
52.3M
-22.91% -54.00%
-2.55
0.91
17.61% 19.28%
3.8M
3.7M
-16.18% 262.50%
-0.31
1.01
5.77% 8.23%

Hologic Inc News

Latest updates
Defense World17 hours ago
Yahoo Finance12 Apr 202402:45 pm
Yahoo Finance02 Apr 202407:00 am

Hologic Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue7.2%1,0139459841,0271,0749531,0031,4361,4711,3171,1681,5381,6101,347823756851866852818831
Gross Profit13.4%5685003685866185155509479868287021,0861,18093246639643425044542.00434
Operating Expenses0.4%369368366314356374286353345389343289295299275239309336300366294
  S&GA Expenses6.7%149140150142164159152171147159143132128126104111145142144134146
  R&D Expenses-8.4%67.0073.0073.0074.0075.0076.0065.0070.0073.0077.0069.0072.0059.0057.0055.0049.0061.0060.0061.0057.0053.00
EBITDA Margin-3.4%0.21*0.22*0.22*0.27*0.31*0.36*0.39*0.39*0.42*0.45*0.49*0.49*---------
Interest Expenses-7.5%26.0028.0028.0027.0028.0024.0023.0023.0026.0023.0022.0021.0028.0025.0027.0031.0033.0035.0035.0035.0036.00
Income Taxes-200.4%-55.2055.0053.0061.0052.0025.0020.0011912382.0069.0016117912432.0024.00-2881.0020.00-81.106.00
Earnings Before Taxes31.4%19114612.0027923914324857462241133878183261716811997.00-122114-353104
EBT Margin-5.6%0.16*0.17*0.17*0.22*0.27*0.33*0.36*0.36*0.39*0.42*0.45*0.45*---------
Net Income172.1%24791.00-40.5021918711922845649932926861965349413695.00386-12394.00-27299.00
Net Income Margin14.7%0.13*0.11*0.12*0.19*0.22*0.27*0.29*0.29*0.31*0.33*0.36*0.36*---------
Free Cashflow-18.3%1732122861592061222841,015517418643533---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-7.3%8,4709,1399,3389,4499,2909,0719,3579,5159,2858,9208,5918,0447,5517,1966,8036,8226,3126,4426,5226,5256,932
  Current Assets-16.5%3,4944,1854,3394,2114,0213,8623,9093,8813,5063,1692,4182,6622,5962,2221,9831,9371,6381,7931,5921,5111,402
    Cash Equivalents-29.0%1,9322,7232,7652,5822,4412,3402,3752,2911,4211,170828816869701744800382602428401311
  Inventory2.6%634618680688678624581526518501503456420395414401381445468443419
  Net PPE1.9%527517493498494482490507554565551534515492456445452471470470473
  Goodwill0.7%3,3063,2813,2983,2973,2903,2373,2863,3173,3293,2824282,85732.002,6582,5932,5922,5942,5642,566--
  Current Liabilities-25.5%8991,2079819559569381,0011,3051,2791,3271,4651,0361,0561,2391,3461,4811,0431,0701,0151,0451,078
  Long Term Debt-0.3%2,5232,5312,7892,7982,8062,8082,8152,8132,8202,7122,6552,6722,6902,7142,7312,7492,7692,7842,7922,8002,808
    LT Debt, Current-87.0%37.0028732.0026.0021.0015.008.0025624931346175.0075.00325566750302271234311319
    LT Debt, Non Current-0.3%2,5232,5312,7892,7982,8062,8082,8152,8132,8202,7122,6552,6722,6902,7142,7312,7492,7692,7842,7922,8002,808
Shareholder's Equity-7.2%4,6545,0175,1825,3015,0934,8764,9984,7934,5194,2193,8773,7953,2692,7072,2592,0912,2582,1162,2172,1602,394
  Retained Earnings12.0%2,3032,0561,9662,0061,7881,6001,4821,253798298-30.50-298-918-1,573-2,068-2,206-2,302-2,688-2,565-2,659-2,386
  Additional Paid-In Capital-1.3%6,0596,1416,1236,0926,0616,0436,0175,9975,9645,9665,9365,9275,8955,9055,8625,8285,7505,7705,7395,7235,686
Shares Outstanding-3.3%239247247248247252252252253257256259---------
Minority Interest------------1.001.002.004.005.007.00----
Float----19,638---18,758---18,639---8,530---12,895-
Cashflow (Last 12 Months)
(In Millions)
Cashflow (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations-15.0%2202593332062531693311,062564465663552650442223118114248164134105
  Share Based Compensation51.1%29.0019.0017.0023.0021.0015.0015.0018.0019.0014.0015.0017.0019.0030.0020.0016.0018.0014.0014.0018.0017.00
Cashflow From Investing-86.1%-104-56.00-38.70-16.40-41.00-32.10-9.809.00-173-43.10-758-478-49.90-137-36.3078.00-45.70-80.80-32.80-36.40-130
Cashflow From Financing-348.1%-943-210-109-49.50-113-169-240-202-143-82.00110-129-428-350-241223-2899.00-104-8.00-328
  Buy Backs220.5%67721111450.00100175-2001670.00188120101100-0.10268286-50.003.00147

HOLX Income Statement

2023-12-30
Consolidated Statements of Income - USD ($)
shares in Thousands, $ in Millions
3 Months Ended
Dec. 30, 2023
Dec. 31, 2022
Revenues:  
Product$ 828.1$ 886.3
Service and other185.0187.9
Revenues1,013.11,074.2
Costs of revenues:  
Product307.2296.2
Amortization, Cost of Goods Sold45.555.6
Service and other92.9104.5
Gross profit567.5617.9
Operating expenses:  
Research and development66.874.8
Selling and marketing148.9163.5
General and administrative111.8108.5
Amortization of acquired intangible assets13.37.6
Impairment of intangible asset4.30.0
Contingent consideration - fair value adjustment1.70.0
Restructuring charges22.51.1
Operating expenses369.3355.5
Income from operations198.2262.4
Interest income27.920.6
Interest expense(26.0)(28.1)
Other expense, net(8.8)(15.8)
Income before income taxes191.3239.1
Provision (benefit) for income taxes(55.2)51.7
Net income$ 246.5$ 187.4
Net income per common share:  
Basic (in usd per share)$ 1.03$ 0.76
Diluted (in usd per share)$ 1.03$ 0.75
Weighted average number of shares outstanding:  
Basic (in shares)238,627247,319
Diluted (in shares)240,214249,281

HOLX Balance Sheet

2023-12-30
Consolidated Balance Sheets - USD ($)
$ in Millions
Dec. 30, 2023
Sep. 30, 2023
Current assets:  
Cash and cash equivalents$ 1,932.1$ 2,722.5
Accounts receivable, less reserves670.9625.6
Inventory633.6617.6
Prepaid Expense, Current155.8175.3
Prepaid Income Taxes-Current101.831.6
Disposal Group, Including Discontinued Operation, Assets0.011.9
Total current assets3,494.24,184.5
Property, plant and equipment, net527.0517.0
Intangible assets, net832.7888.6
Goodwill3,305.93,281.3
Other assets309.7267.9
Total assets8,469.59,139.3
Current liabilities:  
Current portion of long-term debt37.4287.0
Accounts payable183.8175.2
Accrued expenses484.0534.6
Deferred revenue190.6199.2
Finance lease obligations3.23.1
Disposal Group, Including Discontinued Operation, Liabilities, Current0.08.2
Total current liabilities899.01,207.3
Long-term debt, net of current portion2,522.72,531.2
Finance lease obligations, net of current portion14.715.3
Deferred Income Tax Liabilities, Net19.820.2
Deferred revenue, net of current portion14.213.8
Other long-term liabilities345.3334.6
Stockholders’ equity:  
Preferred stock, $0.01 par value – 1,623 shares authorized; 0 shares issued0.00.0
Common stock, $0.01 par value – 750,000 shares authorized; 300,496 and 299,940 shares issued, respectively3.03.0
Additional paid-in-capital6,058.76,141.2
Retained earnings2,302.82,056.3
Treasury stock, at cost – 65,952 and 58,231 shares, respectively(3,591.9)(3,036.0)
Accumulated other comprehensive loss(118.8)(147.6)
Total stockholders’ equity4,653.85,016.9
Total liabilities and stockholders’ equity$ 8,469.5$ 9,139.3
HOLX
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalovirus; Aptima BV and Aptima CV/TV assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. It also offers solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology, and treatment, such as 2D and 3D digital mammography systems, image analytics software, reading workstations, ultrasound imaging, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and ultrasound and connectivity solutions, as well as breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology in the uterus; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; and the CoolSeal portfolio that includes bipolar vessel sealing devices. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
 CEO
 WEBSITEhologic.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES6944

Hologic Inc Frequently Asked Questions


What is the ticker symbol for Hologic Inc? What does HOLX stand for in stocks?

HOLX is the stock ticker symbol of Hologic Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Hologic Inc (HOLX)?

As of Mon Apr 15 2024, market cap of Hologic Inc is 18.21 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of HOLX stock?

You can check HOLX's fair value in chart for subscribers.

What is the fair value of HOLX stock?

You can check HOLX's fair value in chart for subscribers. The fair value of Hologic Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Hologic Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for HOLX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Hologic Inc a good stock to buy?

The fair value guage provides a quick view whether HOLX is over valued or under valued. Whether Hologic Inc is cheap or expensive depends on the assumptions which impact Hologic Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for HOLX.

What is Hologic Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, HOLX's PE ratio (Price to Earnings) is 35.34 and Price to Sales (PS) ratio is 4.59. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HOLX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Hologic Inc's stock?

In the past 10 years, Hologic Inc has provided 0.141 (multiply by 100 for percentage) rate of return.